Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06689020
Starting soon Observational

Positive Expiratory Pressure (PEP) and Continuous High-frequency Oscillation (CHFO) on Lung RECRUITment Using Electrical Impedance Tomography (EIT) - The PEP-RECRUIT Study

NCT06689020 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Genova
Phase
Observational
Started
2024-12-01
Last updated
2024-11-14

Condition(s) studied

RecruitmentRespiratory Failure

Investigational drug(s) / intervention(s)

Continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP) therapy

Continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP) therapy: During application of CPEP and CHFO, EIT is monitored.

Study summary

This single-center observational study aims to assess the effects of continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP) therapy on lung recruitment using electrical impedance tomography (EIT) in spontaneously breathing patients admitted to the intensive care unit.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients who require pulmonary expansion and airway clearing as per clinical indication * Patients who provide valid informed consent according to local regulations * PaO2/FiO2 \< 200 mmHg at inclusion * Patient on the Airway Care Score (ACS) \< 7 Exclusion Criteria: * Refuse to participate * Age \< 18 years * Hemodynamic instability, defined as systolic arterial pressure \< 90 mmHg or mean pressure \< 60 mmHg * Contraindication to using an EIT (i.e., pacemaker or defibrillator) * Inability to properly position the EIT device for anatomical reasons

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
UO Clinica Anestesiologica e Terapia Intensiva, IRCCS Ospedale Policlinico San Martino Genova GE

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06689020 on ClinicalTrials.gov ↗ ← All trials in Italy